Article
Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study.
Journal of hepatology - 1 Jan 2003
Akuta Norio, Tsubota Akihito, Suzuki Fumitaka, Suzuki Yoshiyuki, Hosaka Tetsuya, Someya Takashi, Kobayashi Masahiro, Saitoh Satoshi, Arase Yasuji, Ikeda Kenji, Kumada Hiromitsu
Abstract excerpt
BACKGROUND/AIMS: Comparison of long-term prognosis in patients with chronic hepatitis B treated with lamivudine, with or without severe acute exacerbation (SAE). METHODS: In chronic hepatitis B HBeAg-positive patients on lamivudine monotherapy, 21 patients with SAE were retrospectively compared with 63 patients without SAE. Both groups were matched for age and sex. We investigated the efficacy and problems...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.